Loading…
Gamma‐glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non‐alcoholic fatty liver disease
Background and Aim It is unclear whether changes in lipid profile and liver biochemistry are associated with advanced fibrosis. Methods Patients diagnosed with non‐alcoholic fatty liver disease (NAFLD) between 2009 and 2017 were included. The changes in blood tests were calculated as follows: [(valu...
Saved in:
Published in: | Journal of gastroenterology and hepatology 2022-08, Vol.37 (8), p.1624-1632 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background and Aim
It is unclear whether changes in lipid profile and liver biochemistry are associated with advanced fibrosis.
Methods
Patients diagnosed with non‐alcoholic fatty liver disease (NAFLD) between 2009 and 2017 were included. The changes in blood tests were calculated as follows: [(value at 6 months − value at baseline)/value at baseline] × 100. The endpoint was advanced fibrosis determined by the NAFLD fibrosis score, calculated every year from diagnosis until 2019. Cox proportional hazards models were used to identify factors predicting advanced fibrosis.
Results
After a median follow‐up of 31.7 (19.4–50.8) months, advanced fibrosis occurred in 64 (6.3%) of 1021 patients. Gamma‐glutamyl transpeptidase (GGT) levels (72.9 vs 51.1 IU/L; P = 0.23) and ΔGGT (+6.0% vs −6.9%; P = 0.06) were higher in the advanced fibrosis group. ΔGGT (hazard ratio [HR] 1.03; P |
---|---|
ISSN: | 0815-9319 1440-1746 |
DOI: | 10.1111/jgh.15871 |